NCT07911046Not yet recruiting
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This single-site, prospective observational pilot study examines how clinically prescribed semaglutide is associated with changes in the adolescent brain, cognition, mood, interoception, and metabolic and biological markers. Adolescents 12 to 15 years old with obesity (body mass index at or above the 95th percentile for age and sex), whose own treating physician has independently decided to start weekly subcutaneous semaglutide (Wegovy) as part of routine care, complete multimodal assessments before starting the medication and again after approximately 6 months of treatment. Assessments at each timepoint include 3T structural and resting-state functional MRI, a neurobehavioral and interoceptive battery, and saliva and blood collection for biomarker analysis and biobanking; a semi-structured qualitative interview is conducted at the follow-up visit. The study does not provide, prescribe, or modify the medication-all treatment decisions are made by the participant's own physician. The primary goal is to characterize within-subject changes in resting-state functional connectivity, brain structure, cognition, and eating- and reward-related behavior associated with GLP-1 receptor agonist treatment during adolescence, and to interpret these measures relative to normative neuroimaging and cognitive data from the Adolescent Brain Cognitive Development (ABCD) Study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 12 (estimated)
- First submitted
- 26 Oct 2026
- Start date
- Mar 2027
- Primary completion date
- Dec 2028
- Lead sponsor
- Erin Mauney
- Diseases
- Obesity
- NCT number
- NCT07911046
What you commit to
- Study type: Observational
- Planned participants: 12
- From Mar 2027 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or prior use of a GLP-1 receptor agonist, or recent discontinuation
- Current treatment with a GnRH analog or gender-affirming hormone therapy
Other illness
- Any medical, neurological, or developmental condition that, in the investigator's judgment, would prevent completion of study procedures or confound the imaging or cognitive measures
Other
- Any contraindication to MRI (e.g., non-removable implanted metal or electronic device, or fixed metal orthodontic hardware)
- Pregnancy
Who the study is looking for
- Adolescents 12 to 15 years old at enrollment
- Obesity, defined as body mass index (BMI) at or above the 95th percentile for age and sex and below 160% of the 95th percentile
- The participant's own treating physician has independently decided to initiate weekly subcutaneous semaglutide (with a planned maintenance dose of at least 1.7 mg per week) as part of routine clinical care
- Able to undergo magnetic resonance imaging (MRI)
- Parent/guardian permission and participant assent
Age in the registry: 12 years to 15 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tufts Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.